CareDx Announces Q1 2026 Earnings Call Highlights and Strategic Updates
CareDx, Inc. reported Q1 2026 earnings call highlights, including a strategic shift to focus on precision medicine testing and digital solutions, with the divestiture of the Lab Products segment. The company raised its 2026 revenue guidance to $447 million to $465 million and outlined growth expectations from its Navaris acquisition in specialty oncology. The outlook includes increased testing volume and the anticipated resolution of the MolDX draft LCD for transplant testing.
Tickers: $CDNA
Topics: Earnings Guidance M&A Market Expansion Product Launch Revenue Growth Strategic Transformation